Drug Eluting Stent Market (2026-2031) - Rising Cardiovascular Disease Burden Drives Growth

Aging populations, rising CAD and minimally invasive PCI drive demand. Opportunities center on bioresorbable, polymer-free, ultra-thin and magnesium stents, especially in Asia-Pacific.

Dublin, Aug. 28, 2026 (GLOBE NEWSWIRE) -- The "Drug Eluting Stent - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

Drug Eluting Stent Market to Reach USD 13.28 Billion by 2031 as PCI Volumes and Bioresorbable Technologies Advance

The global drug eluting stent market is projected to grow from USD 8.91 billion in 2025 to USD 9.46 billion in 2026 before reaching USD 13.28 billion by 2031. The market is expected to register a compound annual growth rate (CAGR) of 7.03% between 2026 and 2031, supported by the rising prevalence of coronary artery disease, an aging global population, increasing percutaneous coronary intervention (PCI) volumes, and continued innovation in stent materials and polymer coatings.

Coronary Artery Disease and Aging Populations Support Market Growth

The increasing incidence of coronary artery disease remains a major driver of drug eluting stent market growth. The global population aged 65 and older continues to expand, contributing to a higher number of patients presenting with multivessel disease. These cases frequently require two or more stents per procedure, sustaining device demand despite progress in preventive cardiology.

Age-stratified enrollment is increasingly required in pivotal clinical trials, improving the relevance of clinical evidence for older patients. Approximately 40% of interventions are performed in Medicare beneficiaries, highlighting the importance of technologies designed for elderly and high-risk populations. Bioresorbable polymer stents are also gaining attention among patients with chronic kidney disease because they reduce the presence of long-term foreign material after polymer degradation.

Geriatric cardiology organizations in Europe and Japan increasingly support ultra-thin strut platforms combined with abbreviated antiplatelet regimens. This clinical direction aligns with evolving regulatory requirements for age-specific analyses and is expected to encourage broader adoption of advanced drug eluting stent technologies.

Rising PCI Volumes Accelerate Drug Eluting Stent Adoption

Growth in PCI procedures and the preference for minimally invasive cardiovascular interventions are strengthening global demand. Annual PCI volume in the United States reached approximately 550,000 procedures in 2024. Growth is even more pronounced across Asia-Pacific, where China recorded around 950,000 interventions following the expansion of rural insurance coverage.

Radial access and same-day discharge have become increasingly common, helping reduce vascular complications and improve hospital capacity. Drug eluting stents continue to Benefit from favorable clinical performance, with Target -lesion revascularization remaining below 5% at 12 months. This outcome is increasingly reflected in payer performance measures and hospital procurement decisions.

Additional market drivers include advances in polymer coatings, ultra-thin strut platforms, and one-month dual antiplatelet therapy labeling, which can expand the eligible patient population. However, high device and procedure costs continue to limit adoption in lower-income regions.

Regulatory Evidence Requirements Present a Market Restraint

Strict long-term evidence requirements are increasing development costs and extending commercialization timelines. Under Europe's Medical Device Regulation, bioresorbable scaffolds may require five years of follow-up, adding approximately USD 8 million and up to three years to pivotal development programs.

The U.S. Food and Drug Administration increasingly requires head-to-head non-inferiority studies against best-in-class comparators. These studies can expand enrollment to as many as 3,000 participants. Post-market registries covering the first 10,000 implants may also place pressure on smaller manufacturers, although these requirements strengthen long-term safety surveillance and clinical confidence.

Bioresorbable Polymer and Polymer-Free Stents Gain Momentum

Durable polymer devices accounted for 51.44% of the drug eluting stent market in 2025, supported by extensive clinical evidence and established physician familiarity. Bioresorbable polymer platforms, however, are forecast to expand at a CAGR of 10.36% through 2031. Polymer degradation within approximately 12 months can reduce chronic foreign-body reactions and support improved long-term outcomes.

Polymer-free alternatives represented 12% of the market in 2025 and are increasingly associated with abbreviated antiplatelet strategies. Although ISO 10993-13 toxicity testing has raised upfront development expenses, the resulting evidence has improved clinician confidence in bioresorbable and polymer-free technologies.

Durable polymer stents remain important for complex diabetes-associated lesions requiring extended drug delivery, but broader use is gradually shifting toward Next -generation platforms. Results presented from the BIOFLOW-VI trial at ACC 2025 indicated 25% lower late stent thrombosis with bioresorbable coatings beyond two years. These findings may accelerate the transition toward thinner and faster-absorbing polymer technologies.

Advanced Stent Materials Reshape Product Development

Cobalt-chromium alloys held 37.66% of the market in 2025 and remain widely used in drug eluting stent manufacturing. Magnesium alloy composites are projected to grow at an 11.77% CAGR as full resorption within 12 months offers the potential to restore vasomotion.

Platinum-chromium alloys accounted for 28% of the market and can support strut thicknesses of approximately 60 micrometers while retaining the radial strength required for calcified vessels. Stainless steel has declined to a single-digit share as clinicians increasingly prioritize thinner struts and accelerated endothelialization. ISO 10993-15 animal-model degradation studies have extended development timelines but have also helped address toxicity concerns surrounding novel metals.

Regional Drug Eluting Stent Market Outlook

North America generated 39.43% of global revenue in 2025, supported by PREMIUM pricing for bioresorbable platforms and one-month antiplatelet therapy labeling. The expanded labeling increased the potential treatment population by an estimated 150,000 cases. Although drug-coated balloons are capturing a growing share of in-stent restenosis procedures, the adoption of artificial intelligence-guided imaging is helping sustain regional demand.

Asia-Pacific is forecast to be the fastest-growing regional market, advancing at a CAGR of 9.21% through 2031. China's annual PCI volume is approaching 1 million procedures, while domestic manufacturers are offering devices priced below USD 600 to meet emerging-market affordability requirements. Harmonized submission pathways across Japan, South Korea, Taiwan, and ASEAN markets are also streamlining market access and supporting regional expansion.

Europe continues to face longer approval timelines and higher evidence-generation costs under the Medical Device Regulation. Nevertheless, increasing PCI-to-coronary artery bypass grafting ratios and support for shorter dual antiplatelet therapy regimens are maintaining demand. The Middle East and Africa account for approximately 6% of the market, with adoption constrained by device costs, while investment in catheterization laboratory infrastructure across Gulf Cooperation Council countries is improving procedure capacity. South America holds an estimated 8% share, led by Brazil's approximately 180,000 annual PCI procedures and expanding reimbursement coverage in Argentina and Chile.

Key Topics Covered:

1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Coronary Artery Disease & Aging Population
4.2.2 Growth in PCI Volumes & Preference for Minimally-Invasive Interventions
4.2.3 Advances in Polymer Coatings & Ultra-Thin Strut Platforms
4.2.4 One-Month DAPT Labeling Expanding Eligible Patient Pool
4.2.5 Domestic Low-Cost DES Production Boosting Adoption in Emerging Asia
4.2.6 AI-Guided Intravascular Imaging Improving Stent Placement Success
4.3 Market Restraints
4.3.1 Stringent Long-Term Regulatory Evidence Requirements
4.3.2 High Device & Procedure Cost in Low-Income Regions
4.3.3 Supply-Chain Vulnerabilities in Medical-Grade Polymers & Apis
4.3.4 Competitive Cannibalization from Drug-Coated Balloons In ISR/Small Vessels
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)
5.1 By Coating Type
5.1.1 Durable Polymer-based
5.1.2 Bioresorbable Polymer-based
5.1.3 Polymer-free
5.2 By Material
5.2.1 Cobalt-Chromium Alloy
5.2.2 Platinum-Chromium Alloy
5.2.3 Stainless Steel
5.2.4 Nitinol
5.2.5 Magnesium Alloy / Composite
5.3 By Drug Type
5.3.1 Sirolimus & Analogues (Everolimus, Zotarolimus, Biolimus A9)
5.3.2 Paclitaxel
5.3.3 Dual-therapy / Combination-drug Stents
5.4 By Application
5.4.1 Coronary Artery Disease
5.4.2 Peripheral Artery Disease
5.5 By End User
5.5.1 Hospitals
5.5.2 Cardiac Catheterization / PCI Centers
5.5.3 Ambulatory Surgical Centers
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 France
5.6.2.3 United Kingdom
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 South Korea
5.6.3.5 Australia
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East & Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East & Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America

6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.3.1 Abbott
6.3.2 Alvimedica
6.3.3 B. Braun Melsungen AG
6.3.4 Balton Sp.z.o.o
6.3.5 Biosensors International Group, Ltd.
6.3.6 Biotronik SE & Co. KG
6.3.7 Boston Scientific Corporation
6.3.8 Cook Medical Inc.
6.3.9 Elixir Medical Corporation
6.3.10 Johnson & Johnson Services LLC
6.3.11 JW Medical Systems
6.3.12 Lepu Medical Technology Co., Ltd.
6.3.13 Medtronic plc
6.3.14 Meril Life Sciences Pvt. Ltd.
6.3.15 MicroPort Scientific Corporation
6.3.16 OrbusNeich Medical
6.3.17 Sahajanand Medical Technologies Pvt. Ltd.
6.3.18 Sino Medical Sciences Technology Inc.
6.3.19 Terumo Corporation
6.3.20 Translumina GmbH

7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-Need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/iwywe2

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900